Assembly Biosciences Inc – Bilanz (NASDAQ:ASMB) | MetaTrader

Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik

Vierteljährlich Jährlich

Gesamtvermögen 283.25 M191.06 M101.79 M136.82 M119.17 M257.59 M Gesamtverbindlichkeiten 42.68 M22.13 M19.13 M95.73 M85.81 M50.84 M Gesamtkapital 240.58 M168.93 M82.66 M41.1 M33.36 M206.75 M Gesamtverbindlichkeiten und Eigenkapital 283.25 M191.06 M101.79 M136.82 M119.17 M257.59 M Gesamtverschuldung —————— Nettoverschuldung ——————

Nachrichten

Fortschritte bei Herpes-Medikament: Guggenheim hebt Kursziel für Assembly Biosciences an

Assembly Biosciences: 'Buy' On HPI Program Opt-In And HDV Candidate Development (ASMB)

Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates

Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates

Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates

Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates

GILD Exercises Option to License Assembly Bio's Herpes Programs

Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes - Assembly Biosciences (NASDAQ:ASMB), Gilead Sciences (NASDAQ:GILD)

Gilead exercises option for Assembly Bio’s herpes treatment programs

Assembly Biosciences: Jefferies hebt Kursziel nach positiven HSV-Daten deutlich an

Jefferies raises Assembly Biosciences stock price target to $62 on HSV data

Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript